Lisdexamfetamine dimesylate: A guide to its use in attention-deficit hyperactivity disorder

Drugs and Therapy Perspectives

Volumn 26, Issue 10, 2010, Pages 1-5

[No Author Info available]

Author keywords

Amphetamines; Attention deficit hyperactivity disorder; Lisdexamfetamine; therapeutic use; treatment

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; CHLORPROMAZINE; DEXAMPHETAMINE; DEXTROPROPOXYPHENE; ETHOSUXIMIDE; HALOPERIDOL; LISDEXAMFETAMINE; LITHIUM CARBONATE; METHENAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PETHIDINE; PHENOBARBITAL; PHENYTOIN; TRICYCLIC ANTIDEPRESSANT AGENT; VERATRUM ALKALOID;

ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CHILD GROWTH; CLINICAL TRIAL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; HEADACHE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERACTIVITY; HYPERTENSION; INSOMNIA; IRRITABILITY; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; PATIENT SELECTION; RASH; SCHOOL; SHORT SURVEY; SIDE EFFECT; TACHYCARDIA; TIC; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; WORKPLACE; XEROSTOMIA;

EID: 77956328670     PISSN: 11720360     EISSN: 11791977     Source Type: Journal    
DOI: 10.2165/11205310-000000000-00000     Document Type: Short Survey

References (17)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366 (9481): 237-248
2. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007 Jan; 21 (1): 10-41
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association, 2000
4. Pennick M. Absorption of lisdexamfetamine dimesylate and hydrolysis to form the active moiety, d-amphetamine [poster]. 49th Annual New Clinical Drug Evaluation Meeting; 2009 Jun 29-Jul 2; Hollywood (FL)
5. Biederman J, Boellner S, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007 Nov 1; 62 (9): 970-976
6. Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol. Epub 2010 Feb 19
7. Vyvanse® (lisdexamfetamine dimesylate) capsules: US prescribing information. Wayne (PA): Shire US. Inc., 2010 Apr
8. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009 Jun 23 (4): 419-427
9. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009 Jun; 23 (4): 410-418
10. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008 Jan; 24 (1): 33-40
11. Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 2010 Jun 24; 6: 34
12. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008; 69: 1364-1373
13. Weisler R, Young J, Mattingly G, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. CNS Spectr 2009 Oct: 14 (10): 573-585
14. Wigal SB, Kollins SH, Childress AC, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009 Jun 9; 3 (1): 17
15. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007 Mar; 29 (3): 1-14
16. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008 Jul; 13 (7): 614-620
17. Faraone SV, Spencer T, Kollins S, et al. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry 2010 Jan; 49 (1): 24-32